Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: Subgroup analyses of ARASENS

Autor:	B. Tombal, F. Saad, K. Fizazi, C.N. Sternberg, E.D. Crawford, C. Gratzke, M. Grabbert, A. Vilaseca, N. Shore, E. Kopyltsov, M. Bögemann, S. Kapur, S. Srinivasan, F. Verholen, I. Kuss, H. Joensuu, M.R. Smith, M. Hussain
Rok vydání:	2023
Předmět:	Urology
Zdroj:	European Urology. 83:S1707-S1708
ISSN:	0302-2838
DOI:	10.1016/s0302-2838(23)01221-6
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::118d6f8123428790785b509f86f9bad5 https://doi.org/10.1016/s0302-2838(23)01221-6 Zobrazit plný text záznamu Full Text from ScienceDirect